Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform
Javelin Biotech today announced a landmark scientific publication, titled "Interconnected multi-microphysiological systems and PBPK modeling for predicting human pharmacokinetics”, in the "Breakthrough" special issue of Lab on a Chip. The study details a liver-centric multi-tissue chip (MTC) platform designed to capture the complex pharmacokinetic (PK) profiles of small-molecule drugs.
Javelin Biotech Strengthens Board with Robin Robinson as Drug Discovery Shifts Towards Human-Based Models
Javelin, a pioneer in human-centric preclinical drug discovery, today announced the appointment of Robin Robinson, PhD to its Board of Directors, effective February 2025. This strategic addition comes at a pivotal time, as the pharmaceutical industry accelerates its transition from traditional animal models to advanced human-based approaches in drug development.
